--- title: "After the holiday, new stocks are \"piling up,\" and the enthusiasm for new share subscriptions is once again \"heating up.\"" type: "News" locale: "en" url: "https://longbridge.com/en/news/260823289.md" description: "After the National Day holiday, the capital market remains vibrant, with a cluster of new stocks being listed and investors showing high enthusiasm. Aomisen was listed on the Beijing Stock Exchange, with a first-day increase of 347.50%, becoming the market focus. The biopharmaceutical sector's Healthgen Biotechnology and BeBetter Med are also receiving significant attention, with the former focusing on biopharmaceuticals and the latter concentrating on major diseases. The activity in the new stock market reflects the implementation of the innovation-driven strategy, with the technology mainline gradually becoming clearer" datetime: "2025-10-13T03:05:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/260823289.md) - [en](https://longbridge.com/en/news/260823289.md) - [zh-HK](https://longbridge.com/zh-HK/news/260823289.md) generator: "portal-rs" --- # After the holiday, new stocks are "piling up," and the enthusiasm for new share subscriptions is once again "heating up." The National Day holiday has just passed, and the enthusiasm in the capital market remains undiminished. In the first complete trading week after the holiday, new stocks are making a splash, reigniting investors' enthusiasm. Whether it's the soaring debut of Aomisen or the upcoming listings of biopharmaceutical and hard technology companies, they are injecting a dose of "fresh water" into the market, continuing the hot rhythm of new stock trends. The lively capital market after the holiday is not only a release of short-term emotions but also a true reflection of the innovation-driven strategy at the capital end. From intelligent manufacturing to biopharmaceuticals and chip materials, a new stock trajectory centered on technology is gradually becoming clear. ## **1\. Triple Growth Becomes the Focus Again** In the past week, the most eye-catching event was undoubtedly the debut of Aomisen. This company, which focuses on the production of intelligent devices, listed on the Beijing Stock Exchange, becoming a "hot item" in the post-holiday market. According to the issuance announcement, Aomisen's allocation ratio was only 0.0223%, meaning that winning a lottery ticket was akin to "a thousand troops crossing a single-log bridge," indicating the enthusiasm for new stock subscriptions in the market. On its first day, Aomisen's stock price soared, with an average increase of 347.50%. The turnover rate that day was nearly 80%, showcasing astonishing trading activity. The hard technology background combined with stable pricing made Aomisen the focus of capital pursuit. ## **2\. Biopharmaceutical Sector Continues to Be Strong** In the coming week, the new stock market will be very lively, with the listing processes of Healthgen Biotechnology and BeBetter Med, both in the biopharmaceutical sector, attracting significant market attention, as they are both listed on the Sci-Tech Innovation Board. The biopharmaceutical industry is still in a structural growth cycle, with innovative drugs and other sub-sectors continuing to be the focus of capital pursuit. Healthgen Biotechnology is deeply engaged in the research and production of biopharmaceuticals and is an innovative representative of domestic biopharmaceuticals. The company has a strong foundation in recombinant protein drugs and has developed multiple drugs and related research reagents. During the reporting period, Healthgen Biotechnology's operating revenue was 13.3997 million yuan, 24.2641 million yuan, and 25.2161 million yuan, respectively. Due to high R&D investment and lengthy product approval processes, the company has not yet achieved profitability. BeBetter Med focuses on major disease areas such as tumors and autoimmune diseases, standing out in precision medicine with its proprietary technology. The funds raised this time will be used for new drug development. The company is also not yet profitable, but its innovative drug BEBT-908 has already been approved for listing. ## **3\. Leading Silicon Wafer R&D** Another new stock—Xi'an Yicai—will also open for subscription in the coming week. This company specializes in the research, production, and sales of 12-inch silicon wafers and is one of the few companies in China capable of mass production of large silicon wafers. According to the average monthly shipment volume and production capacity statistics for the end of 2024, Xi'an Yicai ranks first in mainland China and sixth globally among 12-inch silicon wafer manufacturers, making it an industry leader. During the reporting period, the company's operating revenue was 1.055 billion yuan, 1.473 billion yuan, and 2.121 billion yuan, with growth rates of 39.62% and 43.99%. Due to prior R&D investments and high fixed costs, the company has not yet achieved profitability With the accelerated development of the chip industry chain, the importance of silicon wafers as a key material is becoming increasingly prominent. Against the backdrop of the current strategy of technological self-reliance and strength, the listing of Xi'an Yicai is expected to add a strong player to the Sci-Tech Innovation Board. Risk Warning and Disclaimer The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial conditions, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at one's own risk ### Related Stocks - [688765.CN](https://longbridge.com/en/quote/688765.CN.md) - [688759.CN](https://longbridge.com/en/quote/688759.CN.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**